SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

Post time 1 hour(s) ago

journal：Annals of Oncology

Authors：A.C. Garrido-Castro; S.E. Kim; T. Li; J. Desrosiers; R. Nanda; Y. Abdou; A.S. Clark; R.L. Sacks; T. O’Connor; N. Sinclair; S. Lo; G. Augdahl; E. Wrabel; M. DiLullo; T. Rahman; A. Patel; M.E. Hughes; J. Baginska; P.B. Lange; T. O’Meara; T.E. Keenan; A. Gorthi; A. D’Ippolito; C.A. Painter; M. Eaton; J.C. Barrett; B. Koca; P.T. Kurnia; A.N. Perry; J. Gomez Tejeda Zanudo; M. He; D.A. Dillon; N.U. Lin; H.J. Burstein; E.A. Mittendorf; R. Jeselsohn; D.L. Rimm; N. Tayob; S.M. Tolaney

Published date：2026-6-

DOI：10.1016/j.annonc.2026.06.012

PDF link：https://www.sciencedirect.com/sc ... 923753426009609/pdf

Article link：https://doi.org/10.1016/j.annonc.2026.06.012

Article Source：Elsevier BV。

Remark：

Post time 1 hour(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[Elsevier] SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[Elsevier] SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer